Core Insights - Sanuwave Health, Inc. has been included in the Russell 2000® Index as part of the 2025 Russell indexes reconstitution, effective June 30, 2025 [1] - The company will also be included in the broader Russell 3000® Index and the Russell Microcap® Index [1] Group 1: Company Overview - Sanuwave Health focuses on the research, development, and commercialization of patented, non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures [4] - The company's wound care portfolio includes regenerative medicine products that assist in restoring normal healing processes [5] - Sanuwave utilizes patented energy transfer technologies across various medical fields, including wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions [5] Group 2: Industry Context - The Russell U.S. indexes encompass the 4,000 largest U.S. stocks ranked by total market capitalization as of April 30 each year [2] - Membership in the Russell 3000® Index leads to automatic inclusion in either the Russell 1000® Index or the Russell 2000® Index, along with relevant growth and value style indexes [2] - As of June 2024, approximately $10.6 trillion in assets were benchmarked to the Russell U.S. indexes, which are maintained by FTSE Russell [3]

Core Insights - Sanuwave Health, Inc. has appointed Greg Bazar to its Board of Directors, bringing extensive experience in engineering, technology, and cybersecurity [1][2][3] - Bazar's background includes founding Simpatico Systems and significant roles at 3D-P and Caterpillar, indicating a strong leadership and innovation track record [2][3] - The company emphasizes interdisciplinary expertise as crucial for its future growth and innovation in wound care technology [3] Company Overview - Sanuwave Health focuses on the research, development, and commercialization of patented, non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures [5] - The company's portfolio includes regenerative medicine products that support the body's natural healing processes across various medical conditions [6] Board Changes - Long-time board member Michael Stolarski is stepping down to focus on personal interests but will remain as a consultant to ensure continuity during the transition [4]

Financial Performance - The company's revenue increased by 29% from $13 million in 2021 to $16.7 million in 2022[7] - Gross profit increased by 57% from $8 million in 2021 to $12.6 million in 2022[7] - Gross margin improved by 13% from 62% in 2021 to 75% in 2022[7] - Operating loss decreased by 41% from ($14.1) million in 2021 to ($8.4) million in 2022[7] - Q4 2022 revenue increased by 29% to $5.5 million compared to $4.3 million in Q4 2021[9] - Q4 2022 gross margin increased by 35% to $4.0 million compared to $2.9 million in Q4 2021[9] - Q4 2022 gross margin percentage improved by 3% to 72%[9] Unit Growth - The company experienced strong unit growth throughout 2022, reaching 220 systems[11] - The company experienced strong unit growth throughout 2022, reaching 180,300 treatments[11] Future Outlook - The company anticipates approximately 14-20% growth in Q1 2023 compared to Q1 2022[13] - The company estimates that achieving 1% market share in the US wound market would equate to $450 million[15]

Financial Performance - The company's revenue increased to $3.8 million in Q1 2023, an 18% increase year-over-year compared to $3.2 million in Q1 2022 [10] - Gross profit increased to $2.5 million in Q1 2023, a 9% increase year-over-year compared to $2.3 million in Q1 2022 [10] - Gross margin was 67% in Q1 2023, a decrease of 500 basis points compared to 72% in Q1 2022 [10] - Operating costs increased to $4.5 million in Q1 2023, a 5% increase year-over-year compared to $4.3 million in Q1 2022 [10] - The company experienced an operating loss of $2.0 million in both Q1 2022 and Q1 2023 [10] Unit Growth - The company sold 217 systems in 2022 [14] - The company sold 180,300 treatments in 2022 [14] - The company sold 28 systems as of March 31, 2023 [14] - The company sold 43,692 treatments as of March 31, 2023 [14] Future Outlook - The company estimates a 15-25% increase in Q2 2023 compared to Q2 2022 [16] - The company estimates that 1% market share in the US wound market would equal $450 million [18]

August 11, 2023 Q2 2023 Update Live Presentation Friday, August 11, 2023, 8:30 AM (EDT) Participant Dial-in Information Toll Free: 1-877-407-0784 Toll/International: 1-201-689-8560 OR click the Call me™ link for instant telephone access to the event. https://callme.viavid.com/viavid/?callme=true&passcode=13732361&h=true&info=company&r=true&B=6 Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 3 Company Financials Q2 2023 Replay Pin Number: 13740603 Replay Expiry: August ...

Financial Performance - Revenue for Q3 2023 reached $5 million, a 19% increase compared to $4.2 million in Q3 2022[15] - Revenue for the nine months ended September 30, 2023, totaled $13.4 million, also a 19% increase compared to $11.2 million for the same period in 2022[15] - UltraMist consumables revenue increased by 24% to $3.1 million, constituting 62% of overall revenues in Q3 2023[15] - Net loss for the three months ended September 30, 2023, was $23.7 million, compared to a net loss of $1.1 million for the same period in 2022, primarily due to non-cash losses on the fair value of derivative liabilities[15] - Adjusted EBITDA loss for Q3 2023 was $0.3 million, an improvement of $1.9 million compared to a loss of $2.2 million in Q3 2022[15] Operational Highlights - 55 UltraMist systems were sold in Q3 2023, an increase from 28 in Q1 2023 and 49 in Q2 2023[15] - Gross margin was 71% for the three months ended September 30, 2023, slightly down from 72% in the same period last year[15] Future Outlook - The company anticipates Q4 2023 revenue will increase approximately 15% to 25% as compared to Q4 2022[17] Corporate Developments - In July 2023, the company issued Asset-Backed Secured Promissory Notes, receiving total proceeds of approximately $3 million[19] - SANUWAVE Health entered into a merger agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp in August 2023, with the combined company expected to trade on Nasdaq under the symbol "SNWV"[19]

Q4 and FY2023 March 22, 2024 Participant Dial-in Information Toll Free: 1-800-267-6316 Toll/International: 1-203-518-9783 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1661785&tp_key=8f8d9c1839 Replay Dial-in Information Live Presentation Friday, March 22, 2024, 8:30 AM (ET) Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 11155229 Replay Expiry: April 15, 2024 2 Forward Looking Statements This presentation may contai ...

Q1 FY2024 May 10, 2024 Live Presentation Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1665712&tp_key=5ceebf04ab Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 1155590 Friday, May 10, 2024, 8:30 AM (ET) Replay Expiry: June 3, 2024 2 Forward Looking Statements This presentation may contain "forward- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2024 SANUWAVE Health, Inc. | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Nevada | 000-52985 | 20-1176000 | | (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | | 11495 Valley View Road ...

November 8, 2024 Q3 FY2024 Participant Dial-in Information Toll Free: 1-800-267-6316 Toll/International: 1-203-518-9783 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1692398&tp_key=e3cff43c54 Live Presentation Friday, November 8, 2024, 8:30 AM (ET) Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 11157276 Replay Expiry: November 29, 2024 2 Forward Looking Statements T ...